Insider · CIK 0001683450
Maegan Adams Ruhlman Cross
Files at PLPC (PREFORMED LINE PRODUCTS CO). First filing -, latest -.
In brief
Maegan Adams Ruhlman Cross files SEC Form 4 as director at PLPC (PREFORMED LINE PRODUCTS CO). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Maegan Adams Ruhlman Cross has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 3 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 9, 2026 | PLPC PREFORMED LINE PRODUCTS CO | GGift Common Shares, $2 par value per shareindirect: by Trust | +18,000 | $0.00 | $0 | 18,000 | Aug 4, 2026 |
| Dec 15, 2025 | PLPC PREFORMED LINE PRODUCTS CO | AGrant or award Common shares, $2 par value | +207 | $0.00 | $0 | 5,972 | Dec 17, 2025 |
| Dec 12, 2024 | PLPC PREFORMED LINE PRODUCTS CO | AGrant or award Common shares, $2 par value | +331 | $0.00 | $0 | 5,765 | Dec 16, 2024 |
Questions about Maegan Adams Ruhlman Cross
Answered from the filings on this page, as of the latest one.
Is Maegan Adams Ruhlman Cross buying or selling?
Maegan Adams Ruhlman Cross has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Maegan Adams Ruhlman Cross's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Maegan Adams Ruhlman Cross has 0.
Where does Maegan Adams Ruhlman Cross file Form 4?
Maegan Adams Ruhlman Cross has filed Form 4 at PLPC (PREFORMED LINE PRODUCTS CO). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.